BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CFO Brian C. Stephenson sold 24,424 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $14.01, for a total transaction of $342,180.24. Following the sale, the chief financial officer now owns 36,408 shares in the company, […]
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CEO Neil Kumar sold 51,552 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $14.01, for a total transaction of $722,243.52. Following the completion of the sale, the chief executive officer now directly owns […]
Aptorum Group (NASDAQ:APM – Get Rating) and BridgeBio Pharma (NASDAQ:BBIO – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Profitability This table compares Aptorum Group and BridgeBio Pharma’s net […]
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) had its price target boosted by Mizuho from $23.00 to $29.00 in a research note issued to investors on Monday, The Fly reports. A number of other equities research analysts have also recently commented on BBIO. The Goldman Sachs Group raised their price target on BridgeBio Pharma from $20.00 […]
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) had its target price boosted by Mizuho from $23.00 to $29.00 in a report released on Monday, The Fly reports. A number of other analysts have also issued reports on the company. The Goldman Sachs Group raised their price target on BridgeBio Pharma from $20.00 to $28.00 and gave […]